Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Ratio Therapeutics | Boston | Series C | $70.0M | 2026-07-31 |
| BigHat Biosciences | San Mateo | Series C | $75.0M | 2026-09-24 |
| Precede Biosciences | Boston | Series B | $63.5M | 2026-01-12 |
| Capstan Therapeutics | San Diego | Series B | $175.0M | 2024-03-20 |
| GlycoEra | Wädenswil | Series B | $130.0M | 2025-05-27 |
| ROME Therapeutics | Cambridge | Series B | $72.0M | 2023-09-12 |
| TORL BioTherapeutics | Culver City | Series C | $96.0M | 2025-10-07 |
| Cour Pharmaceuticals Development | Skokie | Series B | $50.0M | 2026-06-18 |
8 rows of the CSV in 5 of its 18 columns.
- The 20 Bristol-Myers Squibb portfolio companies have raised $4.1B in total.
- 4 of them closed their most recent round in the last 12 months, $258.5M combined.
- The largest of those rounds is BigHat Biosciences' $75.0M Series C, dated September 2026.
- RA Capital Management is an investor in 5 of them, more than any other fund.
- Biotech is the most common sector, with 20 companies (100%).
- 25% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (50% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
15 of 20| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| BigHat Biosciences | BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. | Artificial intelligence | San Mateo, United States | Series C | $75.0M | 2026-09-24 | $174.3M | Andreessen Horowitz, Gaingels, 8VC +2 | 51 to 100 | 2019 |
| Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Boston, United States | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development develops nanoparticle technology to reset immune systems in multiple sclerosis patients. | Biotech | Skokie, United States | Series B | $50.0M | 2026-06-18 | $185.5M | Alpha Wave Global, Bristol-Myers Squibb, Alpha Wave Ventures +2 | 51 to 100 | 2015 |
| Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Boston, United States | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
| TORL BioTherapeutics | TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing new therapies. | Biotech | Culver City, United States | Series C | $96.0M | 2025-10-07 | $412.0M | Goldman Sachs, RA Capital Management, Alexandria Venture Investments +2 | 51 to 100 | 2018 |
| GlycoEra | GlycoEra researches and produces extracellular protein degraders for treating autoimmune diseases. | Biotech | Wädenswil, Switzerland | Series B | $130.0M | 2025-05-27 | $179.3M | Sofinnova Partners, Bristol-Myers Squibb, 5AM Ventures +1 | 11 to 50 | 2020 |
| ArsenalBio | ArsenalBio develops programmable CAR T-cell therapies for solid tumors. | Biotech | South San Francisco, United States | Series C | $325.0M | 2024-09-04 | $630.8M | ARCH Venture Partners, Bristol-Myers Squibb, NVentures +1 | 251 to 500 | 2019 |
| Autobahn Therapeutics | Autobahn Therapeutics develops restorative treatments for neuropsychiatric and neuroimmunologic disorders. | Biotech | San Diego, United States | Series C | $100.0M | 2024-07-24 | $208.7M | Insight Partners, Invus, Bristol-Myers Squibb +2 | 11 to 50 | 2017 |
| Pathios Therapeutics | Pathios Therapeutics develops therapies for autoimmune diseases and cancer. | Biotech | Oxford, United Kingdom | Series B | $25.0M | 2024-04-18 | Innovate UK, Canaan Partners, Bristol-Myers Squibb +2 | 1 to 10 | 2017 | |
| Capstan Therapeutics | Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases. | Biotech | San Diego, United States | Series B | $175.0M | 2024-03-20 | $340.0M | RA Capital Management, OrbiMed, Alexandria Venture Investments +2 | 101 to 250 | 2021 |
| Accent Therapeutics | Accent Therapeutics is a biopharmaceutical company. | Biotech | Lexington, United States | Series C | $75.0M | 2024-01-23 | $178.0M | Google Ventures, Mirae Asset Venture Investment, Bristol-Myers Squibb +2 | 11 to 50 | 2017 |
| ROME Therapeutics | ROME Therapeutics develops therapies for cancer and autoimmune diseases by targeting the repeatome. | Biotech | Cambridge, United States | Series B | $72.0M | 2023-09-12 | $199.0M | Andreessen Horowitz, Google Ventures, Alexandria Venture Investments +2 | 11 to 50 | 2020 |
| Metagenomi | Metagenomi uses metagenomics and machine learning to discover genome editing systems for therapeutics. | Artificial intelligence | Emeryville, United States | Series B | $100.0M | 2023-01-05 | $466.7M | RA Capital Management, Bristol-Myers Squibb, Marshall Wace +1 | 101 to 250 | 2018 |
| Cardior Pharmaceuticals | Cardior Pharmaceuticals develops medicines and therapies to treat and prevent heart disease. | Biotech | Hanover, Germany | Series B | $75.3M | 2021-08-25 | HTGF (High-Tech Gruenderfonds), EQT Life Sciences, Bristol-Myers Squibb +2 | 11 to 50 | 2016 | |
| Personal Genome Diagnostics | Personal Genome Diagnostics analyzes patients' cancer genomes using advanced tools and technologies. | Biotech | Baltimore, United States | Series C | $103.0M | 2021-02-10 | $244.7M | New Enterprise Associates, Sands Capital Ventures, Bristol-Myers Squibb +1 | 101 to 250 | 2010 |
Table 1. Bristol-Myers Squibb portfolio companies: the 15 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 20.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BigHat Biosciences | BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. | Artificial intelligence | San Mateo, United States | Series C | $75.0M | 2026-09-24 | $174.3M | Andreessen Horowitz, Gaingels, 8VC +2 | 51 to 100 | 2019 |
| 2 | Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Boston, United States | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
| 3 | Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Boston, United States | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
| 4 | Cour Pharmaceuticals Development | Cour Pharmaceuticals Development develops nanoparticle technology to reset immune systems in multiple sclerosis patients. | Biotech | Skokie, United States | Series B | $50.0M | 2026-06-18 | $185.5M | Alpha Wave Global, Bristol-Myers Squibb, Alpha Wave Ventures +2 | 51 to 100 | 2015 |
Table 2. Bristol-Myers Squibb portfolio companies: the 4 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Management | Startup incubator | Boston, United States | 5 | 25% | ||
| 2 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 4 | 20% | ||
| 3 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 2 | 10% | 1 | BigHat Biosciences |
| 4 | 8VC | Venture capital firm | Austin, United States | 2 | 10% | 1 | BigHat Biosciences |
| 5 | 5AM Ventures | Venture capital firm | Menlo Park, United States | 2 | 10% | 1 | Precede Biosciences |
| 6 | Roche Venture Fund | Corporate venture arm | Basel, Switzerland | 2 | 10% | 1 | Cour Pharmaceuticals Development |
| 7 | Google Ventures | Corporate venture arm | San Francisco, United States | 2 | 10% | ||
| 8 | Blue Owl | Private equity firm | New York, United States | 2 | 10% | ||
| 9 | Alpha Wave Ventures | Corporate venture arm | Miami, United States | 2 | 10% | 1 | Cour Pharmaceuticals Development |
| 10 | Innovate UK | Entrepreneurship program | Swindon, United Kingdom | 2 | 10% | ||
| 11 | The Pags Group | Family office | Boston, United States | 1 | 5% | 1 | Ratio Therapeutics |
| 12 | Schusterman Family Investments | Family office | New York, United States | 1 | 5% | 1 | Ratio Therapeutics |
| 13 | Gaingels | Syndicate | Burlington, United States | 1 | 5% | 1 | BigHat Biosciences |
| 14 | National Institute of Standards and Technology | Government investment office | Gaithersburg, United States | 1 | 5% | 1 | BigHat Biosciences |
| 15 | Qatar Investment Authority | Fund of funds | Doha, Qatar | 1 | 5% | 1 | Precede Biosciences |
Table 3. Bristol-Myers Squibb portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 20 | 100% | $4.1B |
| Health care | 20 | 100% | $4.1B |
| Software | 4 | 20% | $1.3B |
| Artificial intelligence | 2 | 10% | $641.1M |
Table 4. Bristol-Myers Squibb portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Bristol-Myers Squibb portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 16 | 80% |
| United Kingdom | 2 | 10% |
| Switzerland | 1 | 5% |
| Germany | 1 | 5% |
Table 6. Bristol-Myers Squibb portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Francisco | 3 | 15% |
| Boston | 2 | 10% |
| San Diego | 2 | 10% |
| San Mateo | 1 | 5% |
| Wädenswil | 1 | 5% |
| Cambridge | 1 | 5% |
| Culver City | 1 | 5% |
| Skokie | 1 | 5% |
| Emeryville | 1 | 5% |
| Lexington | 1 | 5% |
| South San Francisco | 1 | 5% |
| Baltimore | 1 | 5% |
Table 7. Bristol-Myers Squibb portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| September 2026 | 1 | 25% | $75.0M |
| July 2026 | 1 | 25% | $70.0M |
| June 2026 | 1 | 25% | $50.0M |
| January 2026 | 1 | 25% | $63.5M |
Table 8. Bristol-Myers Squibb portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 20% | $258.5M |
| 2025 | 3 | 15% | $231.2M |
| 2024 | 9 | 45% | $955.0M |
| 2023 | 2 | 10% | $172.0M |
| 2021 | 2 | 10% | $178.3M |
Table 9. Bristol-Myers Squibb portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 5 | 25% |
| 2015 to 2019 | 13 | 65% |
| 2010 to 2014 | 1 | 5% |
| Before 2010 | 1 | 5% |
Table 10. Bristol-Myers Squibb portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 2 | 10% |
| 11 to 50 | 10 | 50% |
| 51 to 100 | 4 | 20% |
| 101 to 250 | 3 | 15% |
| 251 to 500 | 1 | 5% |
Table 11. Bristol-Myers Squibb portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Bristol-Myers Squibb is recorded as one of its investors. On 16 November 2026 that is 20 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 15 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 20 rows: 1 have no round amount, 0 no city and 0 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many Bristol-Myers Squibb portfolio companies are on the list?
- 20, in the file dated 16 November 2026. 4 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 20 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.